Opendata, web and dolomites

NO-GO SIGNED

NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NO-GO project word cloud

Explore the words cloud of the NO-GO project. It provides you a very rough idea of what is the project "NO-GO" about.

opportunity    oab    ecosystem    population    improvement    archangelica    america    prescription    validation    10    performed    500    urgency    recommend    precursor    clinical    prepared    starting    expansion    made    symptoms    2005    prevalence    embarrassment    bodies    health    create    doctors    urinary    fine    extend    over    16    selling    psychological    seize    demonstrating    gt    expensive    depression    complying    trial    natura    roi    effect    gmp    million    75    minimizing    obtain    tune    life    benefit    dropout    active    mass    cultivating    108    natural    sustainable    syndrome    rates    anxiety    efsa    validated    too    pharmacological    relaxing    capacity    bladder    drugs    save    business    landscape    plant    profits    day    vitro    characterization    people    healthcare    treatments    30    saga    standards    claims    clinically    angelica    interactions    iceland    80    nocturia    age    impaired    launched    preserving    sagapro    worldwide    efficiency    safety    icelandic    formulation    small    multiple    patients    leaves    market    regulate    jobs    social    internalize    66    2021    normal    north    vivo    21    iso   

Project "NO-GO" data sheet

The following table provides information about the project.

Coordinator
SAGANATURA EHF 

Organization address
address: SUDURHELLU 8
city: HAFNARFJORDUR
postcode: 221
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Total cost 2˙232˙470 €
 EC max contribution 1˙562˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGANATURA EHF IS (HAFNARFJORDUR) coordinator 1˙562˙729.00

Map

 Project objective

Over Active Bladder (OAB) is a syndrome characterized by several urinary symptoms, like urgency and nocturia. Prevalence is >10% of the population, 500 million people worldwide, and increases with age (>30% over 75 years old). OAB has psychological consequences such as embarrassment, impaired social interactions, depression and anxiety. Current pharmacological treatments for OAB are associated with multiple side effects and 80% dropout rates within 1 year. At Saga Natura we have developed NO-GO, a natural product for improving OAB symptoms, made from the leaves of the Icelandic plant Angelica archangelica. NO-GO’s precursor SagaPro was launched on the market in 2005, becoming Iceland’s top-selling non-prescription urinary product. We have performed in vivo and in vitro characterization of SagaPro’s bladder relaxing effect and we have clinically validated SagaPro in a small-scale clinical trial on 66 OAB patients, demonstrating it’s efficiency and safety. In Phase 2 we want to fine-tune our formulation, increase and internalize our production capacity complying with ISO and GMP standards and extend our clinical validation. We will also regulate NO-GO through the EFSA to obtain health claims. This way we will be prepared for our product’s mass expansion in Europe and in North America starting in 2021. This project will create 21 new jobs and profits of €108 Million with ROI of 16.6 after 5 years on the market. End-users will benefit from improvement of symptoms, no side effects, and ability to lead a normal every day life. Doctors will be able to recommend NO-GO to their OAB patients, a product with no side effects, and healthcare bodies will save costs on expensive OAB prescription drugs with too high dropout rates. Finally, with our sustainable approach for cultivating Angelica archangelica we will seize this business opportunity while also preserving the Icelandic landscape, using natural resources and minimizing the impact to the ecosystem.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-GO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-GO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More